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Abstract
Background: Over expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac2-GPs, abbreviated as OAcSGP) has been
demonstrated as a disease-associated antigen on the lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
Achatinin-H, a lectin, has selective affinity towards terminal 9-O-acetylated sialic acids-α2-6-Nacetylated galactosamine.
Exploring this affinity, enhanced expression of OAcSGP was observed, at the onset of disease, followed by its decrease
with chemotherapy and reappearance with relapse. In spite of treatment, patients retain the diseased cells referred to as
minimal residual disease (MRD) responsible for relapse. Our aim was to select a suitable template by using the differential
expression of OAcSGP along with other known CD antigens to monitor MRD in peripheral blood (PB) and bone marrow
(BM) of Indian patients with B- or T-ALL during treatment and correlate it with the disease status.
Methods: A two-year longitudinal follow-up study was done with 109 patients from the onset of the disease till the end
of chemotherapy, treated under MCP841protocol. Paired samples of PB (n = 1667) and BM (n = 999) were monitored
by flow cytometry. Three templates selected for this investigation were OAcSGP+CD10+CD19+  or
OAcSGP+CD34+CD19+ for B-ALL and OAcSGP+CD7+CD3+ for T-ALL.
Results: Using each template the level of MRD detection reached 0.01% for a patient in clinical remission (CR). 81.65%
of the patients were in CR during these two years while the remaining relapsed. Failure in early clearance of lymphoblasts,
as indicated by higher MRD, implied an elevated risk of relapse. Soaring MRD during the chemotherapeutic regimen
predicted clinical relapse, at least a month before medical manifestation. Irrespective of B- or T-lineage ALL, the MRD in
PB and BM correlated well.
Conclusion: A range of MRD values can be predicted for the patients in CR, irrespective of their lineage, being 0.03 ±
0.01% (PB) and 0.05 ± 0.015% (BM). These patients may not be stated as normal with respect to the presence of MRD.
Hence, MRD study beyond two-years follow-up is necessary to investigate further reduction in MRD, thereby ensuring
their disease-free survival. Therefore, we suggest use of these templates for MRD detection, during and post-
chemotherapy for proper patient management strategies, thereby helping in personalizing the treatment.
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Background
Acute lymphoblastic leukaemia (ALL) is a malignant
transformation of lymphoblasts, representing the single
commonest type of cancer in paediatric population. With
the dawn of modern chemotherapy, virtually all children
attain remission and approximately 80% are cured, but
the risk of relapse remains as about 20% patients in clini-
cal remission (CR) harbour residual leukemic blasts
referred to as minimal residual disease (MRD) [1]. The sit-
uation is however dissimilar in India. Data from various
Indian cancer registries suggest occurrence of approxi-
mately 10,000 new cases of childhood ALL every year.
Very few of these patients are adequately treated, and the
majority die from their disease due to post-chemothera-
peutic relapse. This contrasts with present cure rates of
Western countries [2].
Considering this growing number of relapse in patients,
post-chemotherapy, we intended to identify their disease
status during the two-year treatment period. To get to the
bottom of this problem, an unambiguous template for the
identification of a specific combination of CD antigens on
the lymphoblasts was essential, which is easily evident
and stably expressed at the onset of ALL and whose altered
expression could be an index for consistent monitoring of
the disease status, during and post-chemotherapy.
Neuraminic acids commonly known as sialic acids, a fam-
ily of 9-carbon carboxylated monosaccharides are impor-
tant constituents of the cell membrane influencing many
biologic reactions either by reacting with specific surface
receptors or via masking the carbohydrate recognition
sites [3-5]. Amongst the multiple variations of sialic acid,
the most frequently occurring substitutions are O-acetyla-
tion, especially at C-9 position generating a family of 9-O-
acetylated sialoglycoproteins henceforth abbreviated as
OAcSGP. Sialic acid binding lectins and/or monoclonal
antibodies (mAb) is commonly used to study sialylation
patterns [3,6-9]. 9-O-acetylated sialoglycans are detecta-
ble at low levels on normal human B-lymphocytes and
their consistent decrease has been observed in some dis-
ease [3]. Pathological variations of the sialoglycans are
also encountered [10,11]. However, their detailed biolog-
ical significance, especially as a potential biomarker in
ALL remains ambiguous.
The preferential affinity of a lectin, Achatinin-H, towards
terminal  N-acetyl-9-O-acetylneuraminic acids-α2-6-N
acetylated galactosamine (Neu5,9Ac2α2-6GalNAc) [12-
14] allowed us to identify an enhanced disease-associated
expression of molecules having terminal Neu5,9Ac2α2-
6GalNAc as sialo-glycotope on peripheral blood mono-
nuclear cells (PBMC) of ALL patient [3,15-20]. In contrast,
a basal level of expression of OAcSGP in normal individ-
uals and patients with other cross-reactive haematological
disorders such as chronic myeloid leukaemia (CML),
acute myelogenous leukaemia (AML), chronic lym-
phocytic leukaemia (CLL), non-Hodgkin's lymphoma
(NHL), thalassemia and aplastic anaemia confirmed the
specificity of this biomarker [3,15-20]. These OAcSGPs are
highly immunogenic [21-24], found as immune-com-
plexed  OAcSGP in the patients' sera [25], and play a
prominent role in promoting the survival of these lym-
phoblasts [26-28].
Cyto-morphological criteria are insufficient because the
threshold of detection of leukemic cells is only 1–5%.
MRD is usually detected by flow-cytometric immunophe-
notyping or PCR analysis of breakpoint fusion regions of
chromosome aberrations and by detection of clone-spe-
cific immunoglobulin and T-cell receptor gene rearrange-
ments. Modern treatment protocols utilize the biological
and clinical information to tailor the intensity of therapy
to the risk of relapse. Recent MRD study shows that mon-
itoring children at consecutive time point gives clinically
relevant insight into the effectiveness of the treatment
[29,30].
Therefore, in this investigation, our endeavour was to
monitor the differential expression of OAcSGP along with
the aberrant expression of other known B and T lineage-
specific CD antigens from the peripheral blood (PB) and
bone marrow (BM) of paediatric ALL patients at the onset
of the disease and during chemotherapy, as per the
MCP841 protocol. Accordingly, we have longitudinally
monitored 109 patients, each patient providing PB-18
times and BM-11 times respectively throughout the two-
year treatment regimen, by triple colour flow-cytometric
analysis for the detection of MRD, using the same tem-
plate for an individual.
The present study reports (i) high expression of OAcSGP
along with B-(CD10+CD19+  or CD19+CD34+) or T-
(CD7+CD3+) lineage-specific CD markers in paired sam-
ples of PB and BM from individual patients at the onset of
the disease which decreases during clinical remission
(CR), (ii) detection level of MRD to be 1 in 104 lym-
phocytes, (iii) failure in early clearance of these lymphob-
lasts during the initial few weeks of treatment can be a bad
prognosis, associated with high risk of relapse during
maintenance, (iv) high MRD few weeks prior to clinical
relapse, (v) a good correlation between the MRD in PB
and BM in both B- and T-ALL during treatment. Thus, we
propose that MRD detection technique used in this study
may be beneficial for the long term monitoring of the dis-
ease status of these children and for modifying the inten-
sification of chemotherapy accordingly.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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Methods
Clinical samples
The study population included PB and BM from children
detected for ALL, at diagnosis and at various stages of
treatment. The diagnostic samples comprised of males
and females, ratio being 2:1, median age (6 years; range
0.8–16 years) and median presenting white blood cell
count (12 × 109/L, range 0.4 – 1,000 × 109/L). Diagnosis
was established by cytological examination of the BM
smears according to the French-American-British Group
recommendations, belonging to L1 or L2 and by cytoge-
netic study. Immunophenotype of each sample was done
by flow-cytometric analysis using phycoerythrin (PE),
PECy5 and biotin (B) conjugated antibodies against ter-
minal deoxynucleotidyl transferase (TdT), cytoplasmic μ
(cyt-μ), surface membrane Ig (SIg), CD2, CD3, CD4,
CD7, CD8, CD10, CD13, CD19, CD20, CD33, CD34 and
CD45. These children at diagnosis had morphological
blasts ranging between 40–90%. Three groups of patients
were identified based on the presence of certain cell sur-
face antigens. The B-ALL patients were divided into two
groups based on the presence or absence of CD10; those
with more than 60% of CD10+ and CD19+ cells were
placed in one group while the second group had more
than 55% of CD34+ and CD19+ cells. T-ALL patients had
more than 85% CD7+ cells and about 20% CD3+ cells.
These patients concurrently showed high level of OAcSGP
on the lymphoblasts, based on their high binding with
flourescein isothiocyanate (FITC) conjugated Achatinin-
H [15,16,19,20] and high intensity of anti-OAcSGP anti-
bodies in their serum using an in house ELISA at the onset
of disease [22,23]. Venous blood (4 – 5 ml) and BM (100
– 1000 μl) were collected at Kothari Medical Sciences and
sent to Indian Institute of Chemical Biology. Informed
consent was obtained from donors, patients and parents/
guardians. The Institutional Human Ethical Committee as
per the protocol of Indian Council of Medical Research
approved the study.
These children were treated under MCP841 protocol
(two-year duration) as reported by Advani et al [31]. The
phases of treatment were broadly grouped as follows –
induction 1 (0 – 5 weeks), induction 2 (6 – 8 weeks),
repeat induction 1 (9 – 13 weeks) and consolidation (14
– 18 weeks) followed by six cycles of maintenance (each
cycle comprises of about 14 weeks). PB samples were col-
lected at presentation, each week during induction 1,
twice during induction 2, once during repeat induction,
twice during consolidation, at the beginning of mainte-
nance 1 and at the end of each maintenance, being 18
times from each patient while BM samples were collected
at presentation, once during induction 1, induction 2,
repeat induction, consolidation, at the beginning of main-
tenance 1 and at the end of each maintenance, being 11
times from each patient.
In this study 130 children were monitored at diagnosis
with paired samples of PB and BM. However, 21 of them
could not be monitored, as they did not arrive at the
health centre after diagnosis. As this study remains con-
fined to the longitudinal follow-up of the patients during
the treatment protocol of MCP841, we have excluded
these patients from the data represented here. From the
remaining 109 patients, who received treatment from this
health centre for two-years under the MCP841 protocol,
we studied 2675 follow-up samples [PB (n = 1667); BM (n
= 999)]. Controls included normal age matched healthy
individuals (n = 50) of both sexes and other haematolog-
ical diseases like AML, CML, CLL, NHL and aplastic anae-
mia (n = 50).
Probes
The lectin, Achatinin-H was purified from haemolymph
of the African giant land snail Achatina fulica by affinity
chromatography using bovine submaxillary mucin (BSM)
as the affinity matrix [3]. Purified Achatinin-H was filter
sterilized and stored at 4°C. The preferential affinity of
Achatinin-H towards Neu5,9Ac2α2-6GalNAc was estab-
lished [12] and the lectin conjugated with FITC was used
as an analytical probe for all experiments.
The mAbs (BD Biosciences, San Jose, CA) used for the
MRD assay were PE conjugated CD10 or CD34 or CD7
and B conjugated CD19 or CD3. The signals generated by
the B-antibodies were captured using Streptavidin-PerCP.
Flow cytometry
a. Standardization of dose of Achatinin-H
Different doses of FITC-Achatinin-H [0.02–0.2 μg/10 μl,
dilution in TBS-Ca2+], were separately incubated with 1 ×
106 cells, using normal peripheral blood mononuclear
cells (PBMCN), B (REH, ALLP0 and NALM-6)- and T
(CEMC7 and MOLT4) – ALL cell lines along with patients
from other haematological disorders at 4°C, in dark for 1
hour. Cells were analysed using FACSCalibur; Becton
Dickinson, San Jose, CA. Accordingly, the dose of Achat-
inin-H (0.04 μg/10 μl) was selected and used for all sub-
sequent experiments. This dose has been ensured from
time to time to avoid any discrepancy in the MRD detec-
tion.
b. Standardization of dose of Streptavidin-PerCP
Normal and patient PBMC (1 × 106 cells) were separately
incubated with B-CD19 and PE-CD19 at 4°C, in dark for
1 hour. Tubes containing B-CD19 were monitored using
different doses of Streptavidin-PerCP (0.05 – 0.2 μg/10
μl) and the dose (0.05 μg/10 μl) giving similar binding
with respect to PE-CD19 was selected for MRD assay. Iso-
type matched negative control was used for every assay.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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c. Assessment of expression of OAcSGP along with other lineage-
specific markers
Based on the anomalous differential expression of the cer-
tain cell surface proteins, the patients were classified
broadly into three groups, OAcSGP+CD10+CD19+ or OAc-
SGP+CD34+CD19+ for B-ALL and OAcSGP+CD7+CD3+ for
T-ALL. These differential expressions have been moni-
tored to differentiate normal versus. diseased cells in a par-
ticular sample. Briefly, clinical samples were diluted in
Alsevers solution in the ratio of 1:1, layered on an equal
volume of Ficoll-Hypaque and centrifuged at 1000 rpm
for 1 hour. The mononuclear cells (MNCs) were separated
and washed twice in phosphate buffered saline (PBS, pH
7.2) and suspended in RPMI-1640 supplemented with 2
mM glutamine, gentamycin and FCS (10%) for 1 hour in
ice. MNCs (1 × 106/100 μl) were initially incubated with
FITC-Achatinin-H followed by incubation with PE and B
conjugated anti-CD mAbs in ice for 1 hour, in dark, com-
bination of probes for a particular patient being OAc-
SGP+CD10+CD19+  or  OAcSGP+CD34+CD19+  for B-ALL
and OAcSGP+CD7+CD3+ for T-ALL. The cells were washed
in PBS and incubated with Streptavidin-PerCP. Finally
they were washed thrice in PBS, fixed in paraformalde-
hyde (1%) and the binding was monitored in a flow
cytometer (FACSCalibur, Becton Dickinson, San Jose,
CA). Irrelevant mAbs of the same isotype as in the triplet
combinations, conjugated with the same fluorochromes,
were used as negative controls. Analysis and calculations
were performed using CellQuestPro software (B.D. Bio-
sciences). MNCs were gated for lymphocytes by staining
with anti-CD45 mAb with > 98.0% positive cells. All
blood samples were processed, fixed and acquired within
24 hours, from the time of collection maintaining all con-
ditions rigidly during MRD assay.
d. Acquisition of samples
For MRD detection, at the time of acquisition, the rate of
flow of the cells is kept below 300 events/sec (in RUN-LO
mode) in FACSCalibur so that all the cells are properly
analysed. Forward Scatter (FSC) and Side Scatter (SSC) are
kept in linear scale at the time of acquisition. The cells in
the region 400–600 of FSC are gated as the lymphoblasts
(Region, R1) and 1,00,000 events in R1 are recorded.
e. Evaluation of minimum number of OAcSGP+CD10+CD19+, 
OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+ cells as MRD from 
a mixed population
To estimate the minimal number of OAc-
SGP+CD10+CD19+,  OAcSGP+CD34+CD19+  or  OAc-
SGP+CD7+CD3+  cells in a heterogeneous population,
lymphoblasts from diagnostic samples were admixed to
MNCs of patients at various time-points of follow-up dur-
ing chemotherapy in both PB and BM for lineage-unre-
lated leukaemia (e.g. B-ALL lymphoblasts mixed with T-
ALL follow-up BM and vice-versa) in varying proportions
(1:1, 1:10, 1:100, 1:1000 and 1:10000), keeping the total
cell number constant (1 × 106) and processed for MRD
assay. Similarly, the MRD assay was repeated by admixing
cells from B – (REH) and T – (MOLT4) ALL cell lines sep-
arately with PBMCN to detect OAcSGP+CD10+CD19+ or
OAcSGP+CD7+CD3+ population.
f. Statistical analysis
Statistical analysis was performed using the Graph-Pad
Prism statistics software program (Graph-Pad Software
Inc., CA). Results are expressed as Mean ± SD for individ-
ual set of experiments. The sensitivity and specificity of
the assays were calculated as per the standard formulae.
Results
Optimisation of Achatinin-H to evaluate the status of 
OAcSGP for MRD detection
Minimal expression of cell surface OAcSGP (5–10% of
OAcSGP+ cells, mean fluorescence intensity, MFI, being
~10–50 au) on PBMCN was evidenced using FITC-Achat-
inin-H (0.04 μg/10 μl). With this dose of FITC-Achatinin-
H, more than 90% cells from T- and B-ALL cell lines were
positive for the presence of OAcSGP (MFI being ~100–
700 au), establishing it as a vital disease-associated deter-
minant. This dose of lectin gave a minimal binding with
PBMC of other haematological disorders (5–10%).
Analysis of the data using CellQuestPro software
For the detection of MRD, the MNCs were gated as R1,
based on the FSC and SSC as previously discussed in
Methods section (Figure 1a). These MNCs in the R1 region
are assessed for the binding of PE-CD10/PE-CD34/PE-
CD7, as the case may be, in a dot-plot comprising PE ver-
sus SSC. The region positive for the PE probe is gated as R2
(Figure 1b). The cells in the R2 region are observed in a
third dot-plot with FITC-Achatinin-H vs. PerCP-CD19/
CD3 as the case may be. The upper right quadrant, which
is positive for both FITC and PerCP, is gated as R3 (Figure
1c). Thus this R3 region is positive for all the three mark-
ers (i.e., OAcSGP plus two other lineage-specific markers,
either for B- or T-lineage ALL), recognizing the lymphob-
last population expressing all the three markers viz. OAc-
SGP+CD10+CD19+  or  OAcSGP+CD34+CD19+  or
OAcSGP+CD7+CD3+. The R3 gating is kept fixed for each
patient, whose PB and BM are monitored 18 and 11 times
respectively, as per protocol MCP841 and the number of
cells in this region is used as the percent of MRD in that
patient throughout the treatment phase.
Variable expression of OAcSGP with other lineage-specific 
markers on MNCs at diagnosis and during clinical 
remission (MRD)
a. Status in PB
At the onset of ALL, irrespective of lineage, 40–90% of the
PBMC comprised of the cancerous blasts as per morpho-BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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logical estimation. Percentage of morphological blasts as
estimated by clinicians correlated well with the percentage
of OAcSGP+ cells being about 50–90%. When assessed
using FACS, the percentage of cells positive for OAcSGP
along with two known CD markers viz. OAc-
SGP+CD10+CD19+ (n = 52), OAcSGP+CD34+CD19+ (n =
23) and OAcSGP+CD7+CD3+ (n = 14), are 63.97 ± 9.37,
54.82 ± 6.87 and 61.23 ± 6.25 respectively.
After one week of chemotherapy, there is a sharp decrease
in the percentage of cells expressing all three markers viz.
OAcSGP+CD10+CD19+  (n = 49) or OAc-
SGP+CD34+CD19+ (n = 18) or OAcSGP+CD7+CD3+ (n =
11) being 0.01 ± 0.005, 0.026 ± 0.018 and 0.01 ± 0.005
respectively and is considered as MRD. In this two-year
tenure of treatment, out of the total 109 patients followed
up for the MRD study only 81.65% (n = 89) remained in
clinical remission (CR) with no detectable morphological
blasts. The average MRD of these patients in PB, during
this period, using three-colour flow-cytometric templates
are 0.023 ± 0.01, 0.036 ± 0.015 and 0.03 ± 0.015% for
OAcSGP+CD10+CD19+ (n = 758), OAcSGP+CD34+CD19+
(n = 337) and OAcSGP+CD7+CD3+ (n = 166) template
respectively (Table 1).
b. Status in BM
With an aim to correlate the presence of diseased cells
(MRD), in PB with that of the BM in these 89 patients, BM
from each patient was monitored at different time-points
during chemotherapy, as per the MCP841 protocol. At
diagnosis, the percent of OAcSGP+ cells positive for two
lineage-specific CD markers viz. OAcSGP+CD10+CD19+(n
= 52), OAcSGP+CD34+CD19+  (n = 23) and OAc-
SGP+CD7+CD3+ (n = 14) are 77.61 ± 6.96, 61.84 ± 9.13
and 73.89 ± 7.89 respectively.
As per the protocol, BM received after the initial five doses
of chemotherapy, showed an abrupt reduction in the per-
centage of the above mentioned cell population. The
MRD in BM after five weeks of treatment i.e., at the end of
induction 1 is 0.066 ± 0.028, 0.05 ± 0.028 and 0.03 ± 0.01
percent for the templates OAcSGP+CD10+CD19+ (n = 41),
OAcSGP+CD34+CD19+ (n = 17) and OAcSGP+CD7+CD3+
(n = 12) respectively while the PB collected at the same
time had a MRD of 0.026 ± 0.016, 0.04 ± 0.027 and 0.04
± 0.01 respectively. During longitudinal follow-up, aver-
age MRD in BM of these 89 patients, for templates OAc-
SGP+CD10+CD19+ (n = 443), OAcSGP+CD34+CD19+ (n =
197) and OAcSGP+CD7+CD3+ (n = 96) were 0.05 ± 0.019,
0.055 ± 0.01 and 0.03 ± 0.01 in BM as compared to PB
being 0.023 ± 0.01, 0.036 ± 0.015 and 0.03 ± 0.015
respectively. These patients were in CR (Table 1). A repre-
sentative profile of MRD (OAcSGP+CD10+CD19+ or OAc-
SGP+CD34+CD19+  or  OAcSGP+CD7+CD3+  cells, in R3
gating) in patients from B- and T-lineage ALL has been
shown in Figure 2 where the patients at the end of induc-
Defining the regions R1, R2 and R3 in flow-cytometric dot plots for MRD detection Figure 1
Defining the regions R1, R2 and R3 in flow-cytometric dot plots for MRD detection. a) Forward Scatter (FSC) vs. 
Side Scatter (SSC) in linear mode, showing the region gated for lymphoblasts (400–600), designated as R1. b) Lymphoblasts 
(R1) plotted with PE-(CD10/CD34 for B-ALL and CD7 for T-ALL) vs. SSC. The R2 gate indicates lymphoblasts positive for the 
PE tagged fluorophore. c) Cells in the R2 region are represented in this plot for detecting cells, which are positive for FITC-
Achatinin-H (OAcSGP+) and PerCP-CD19/CD3 for B/T ALL using a multiple gate (R1+R2). Thus the R3 region gates lymphob-
lasts positive for all the three cell surface markers ensuring that every cell in this region is OAcSGP+CD10+CD19+or OAc-
SGP+CD34+CD19+ or OAcSGP+CD7+CD3+ and is defined as the region positive for MRD i.e., cells in this region are the 
residual blasts.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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Table 1: Status of *lymphoblasts (MRD) in ALL patients at various stages of treatment under MCP841 protocol during a two-year 
longitudinal follow-up study.
1Weeks Of 
Treatment
Phases Of 
Treatment
2Disease 
Status
3B-ALL (O 
AcSGP+CD10+CD19+)
3B-ALL (O AcSGP+CD34 
+CD19+)
3T-ALL (O 
AcSGP+CD7+CD3+)
PB BM PB BM PB BM
# 0 Induction 1 Diagnosis 52 (63.97 ± 
9.37)
52 (77.61 ± 
6.96)
23 (54.82 ± 
6.87)
23 (61.84 ± 
9.13)
14 (61.23 ± 
6.25)
14 (73.89 ± 
7.89)
1C R 4 9  ( 0 . 0 1  ±  
0.005)
NR 18 (0.026 ± 
0.018)
NR 11 (0.01 ± 
0.001)
NR
2C R 4 5  ( 0 . 0 2  ±  
0.017)
NR 21 (0.032 ± 
0.031)
NR 8 (0.03 ± 
0.008)
NR
3C R 4 8  ( 0 . 0 4  ±  
0.03)
NR 14 (0.04 ± 
0.022)
NR 10 (0.02 ± 
0.005)
NR
4C R 3 1  ( 0 . 0 2  ±  
0.009)
NR 19 (0.02 ± 
0.017)
NR 9 (0.05 ± 
0.02)
NR
#6 Induction 2 CR 40 (0.026 ± 
0.016)
41 (0.066 ± 
0.028)
22 (0.04 ± 
0.027)
17(0.05 ± 
0.028)
9 (0.04 ± 
0.01)
12 (0.03 ± 
0.01)
8C R 4 4  ( 0 . 0 3 1  ±  
0.015)
NR 17 (0.015 ± 
0.01)
NR 12 (0.027 ± 
0.01)
NR
#10 Repeat 
Induction
CR 47 (0.03 ± 
0.01)
48 (0.061 ± 
0.021)
19 (0.038 ± 
0.032)
21 (0.036 ± 
0.035)
7 (0.04 ± 
0.01)
7 (0.027 ± 
0.01)
14 Consolidation CR 48 (0.02 ± 
0.009)
NR 23 (0.03 ± 
0.007)
NR 12 (0.02 ± 
0.008)
NR
#16 CR 46 (0.02 ± 
0.008)
44 (0.04 ± 
0.025)
13 (0.045 ± 
0.029)
20 (0.065 ± 
0.017)
11 (0.03 ± 
0.021)
9 (0.03 ± 
0.018)
18 CR 47 (0.04 ± 
0.01)
NR 23 (0.036 ± 
0.023)
NR 8 (0.03 ± 
0.01)
NR
#20 Prior to 
maintenance
CR 42 (0.018 ± 
0.011)
47 (0.058 ± 
0.025)
21 (0.04 ± 
0.02)
23 (0.054 ± 
0.017)
9 (0.02 ± 
0.067)
11 (0.03 ± 
0.02)
#34 Maintenance 
1
CR 43 (0.017 ± 
0.008)
46 (0.05 ± 
0.027)
21 (0.038 ± 
0.026)
19 (0.04 ± 
0.01)
11 (0.03 ± 
0.01)
11 (0.023 ± 
0.01)
#48 Maintenance 
2
CR 50 (0.017 ± 
0.011)
42 (0.04 ± 
0.03)
22(0.032 ± 
0.018)
14 (0.063 ± 
0.008)
9 (0.023 ± 
0.01)
8 (0.03 ± 
0.02)
#62 Maintenance 
3
CR 43 (0.03 ± 
0.02)
44 (0.04 ± 
0.01)
23 (0.032 ± 
0.018)
21 (0.055 ± 
0.015)
11 (0.047 ± 
0.02)
10 (0.03 ± 
0.01)
#76 Maintenance 
4
CR 49 (0.02 ± 
0.01)
45 (0.034 ± 
0.008)
22 (0.03 ± 
0.02)
19 (0.062 ± 
0.022)
6 (0.03 ± 
0.01)
10 (0.02 ± 
0.01)
#90 Maintenance 
5
CR 42 (0.04 ± 
0.02)
42 (0.03 ± 
0.01)
18 (0.04 ± 
0.016)
22 (0.02 ± 
0.01)
10 (0.026 ± 
0.01)
10 (0.04 ± 
0.01)
#104 Maintenance 
6
CR 44 (0.02 ± 
0.008)
44 (0.027 ± 
0.003)
21 (0.02 ± 
0.008)
21 (0.034 ± 
0.016)
13 (0.026 ± 
0.02)
8 (0.03 ± 
0.02)
Total 
number of 
samples
810 495 360 220 180 110
* Lymphoblasts with phenotype of OAcSGP+CD10+CD19+, OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+.
1 The samples are received during treatment under MCP841 protocol; PB is received on each of these weeks from each patient, being 18 times per 
patient.
# The number of times BM is received from each patient at various stages of treatment, being 11 times per patient.
2 Diagnosis-newly diagnosed patient prior to treatment. This data has been provided to compare the MRD of the patients at clinical remission CR – 
Clinical Remission; NR – samples were not received in these weeks.
3 Template for detection of minimal residual disease (MRD).
Numbers before parenthesis indicate the number of patients arrived at that point of treatment.
Numbers in parenthesis indicate the % of OAcSGP+ lymphoblasts simultaneously expressing two other known CD markers (CD10, CD19 or CD34, 
CD19 or CD7, CD3) at Diagnosis (prior to treatment, 0 week) and as MRD during CR (during treatment between 1–104 weeks) represented as 
Mean ± SD;
PB – Peripheral Blood; BM – Bone Marrow.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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tion 1 (Figure 2b, e, h and 2k) and in CR (Figure 2c, f, i
and 2l) range around 0.01–0.03% irrespective of PB and
BM. For comparison the presence of OAc-
SGP+CD10+CD19+  or  OAcSGP+CD34+CD19+  or  OAc-
SGP+CD7+CD3+ cells are shown in diagnostic PB (Figure
2a, g) and BM (Figure 2d, j) from the same patients.
Absence of OAcSGP+CD10+CD19+ or 
OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+ cells in 
normal donors and in patients of other haematological 
malignancies
In parallel, the MRD assay was similarly performed with
samples from normal donors and patients with other hae-
Detection of MRD as indicated in the R3 region Figure 2
Detection of MRD as indicated in the R3 region. A representative profile of a B-ALL patient presenting the status of tri-
ple positive cells detected in R3 region viz. OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19+ at the diagnosis is shown in PB 
(a) and BM (d). After the completion of 5 weeks of treatment, the BM sample first received (as per protocol) is compared with 
PB. The MRD (%) of these samples is shown in PB (b) and BM (e) and MRD during CR is shown in PB (c) and BM (f). Similarly, 
the representative profile of a T-ALL patient shows the percentage of OAcSGP+CD7+CD3+ cells at diagnosis in PB (g) and BM 
(j) respectively. MRD (%) in PB and BM is shown in (h, k) after 5 weeks of treatment and (i, l) during CR. PB and BM from B-
ALL patient and T-ALL patient are abbreviated as PBB-ALL, BMB-ALL, PBT-ALL and BMT-ALL respectively.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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matological malignancies. The R3 region (Figure 1c),
defining the MRD in children with ALL, had no visible cell
population in the normal children and in those with
other haematological malignancies, henceforth used as
controls. Moreover MRD could not be detected using Cel-
lQuestPro software thereby confirming that the templates
OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19+ or OAc-
SGP+CD7+CD3+  are specific for childhood leukaemia.
This has been illustrated in Figure 3 where absence of
MRD has been shown in a representative normal donor
and an AML patient. This phenomenon is irrespective of
PB and BM.
Status of regions R2 and R3 in a representative normal donor and an AML patient Figure 3
Status of regions R2 and R3 in a representative normal donor and an AML patient. The R1 region has not been 
shown in this Figure. The R2 region is devoid of any cells for PBN, (a), BMN (c), PBAML (e) and BMAML (g). Consequently, the R3 
region has no cells i.e., no detectable MRD in normal and the AML cases as shown for PBN (b), BMN (d), PBAML (f) and BMAML 
(h). PBN, BMN, PBAML and BMAML represent PB and BM from normal donor and an AML patient respectively.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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Prognostic value of MRD detection using 
OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19+ or 
OAcSGP+CD7+CD3+ template
a. Failure of early clearance of OAcSGP+CD10+CD19+ or 
OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+ lymphoblasts is a 
possible indicator for bad prognosis
In this study population, out of the 109 patients, 20
showed anomalous MRD at different time points of treat-
ment under MCP841 protocol. Among these 20 patients,
a group of 9 patients (8.26% of n = 109) illustrated an
abnormal trend of failure of early clearance of the lym-
phoblasts after the initial few doses of chemotherapy both
in PB and BM (Figure 4, 5). These patients could be iden-
tified within the first induction phase of treatment (0–5
weeks of treatment) and showed a greater chance of
relapse as was evidenced from the clinical relapse encoun-
tered in 6 patients i.e. 5.5% of the patients (n = 109). Inci-
dentally these relapses were detected within the two-year
treatment phase, during the maintenance therapy.
The representative profile of PB and BM from one such B-
ALL patient has been elaborated in Figure 4. After the 5
weeks of treatment (end of induction 1), clearance of
OAcSGP+CD10+CD19+  cells from PB of this patient
(Patient 1) was insufficient as reflected by a 30 fold higher
MRD (Figure 4b) in contrast to that of a representative
patient in CR (Figure 4h). Although MRD (0.04 ± 0.01) of
this child was minimal in between, there was an abnormal
Failure of early clearance of lymphoblasts, during induction 1 of treatment, in R3 region is a poor prognosis increasing the pos- sibility of relapse Figure 4
Failure of early clearance of lymphoblasts, during induction 1 of treatment, in R3 region is a poor prognosis 
increasing the possibility of relapse. The status of OAcSGP+CD10+CD19+, at diagnosis, in PBB-ALL (a) and BMB-ALL (d) of a 
representative profile of a patient is shown. After the fifth week of chemotherapy, the MRD of this patient in PB is high (b) as 
compared to that of another B-ALL patient (h) who is in CR. Similarly the high MRD of this patient in BM (after 5 weeks of 
treatment) is shown (e). The MRD in PB and BM at the time of relapse is shown in (c) and (f) respectively while that of a 
patient having CR throughout the treatment is shown in (i).BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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hike in the MRD being 10.0% in PB on the 48th week cor-
roborated by clinical relapse (Figure 4c). As per protocol,
when BM of this child was received at the end of induction
1, MRD was three fold higher (Figure 4e) in contrast to
patients in CR (Figure 2f), MRD being 0.1 vs. 0.03 (p value
< 0.0001). Consequently, on the 48th week of treatment,
MRD in the BM of this child was very high (20%, Figure
4f) confirming clinical relapse. The lymphoblasts of these
patients in R3 gating, at diagnosis, are shown for compar-
ison in Figure 4a and 4d for PB and BM of Patient 1 and
Figure 4g for PB of Patient 2.
The status of MRD in these 9 patients is elaborately shown
in PB (Figure 5a) and BM (Figure 5b) at different weeks of
treatment. All of them had high MRD in PB (n = 156) dur-
ing induction 1 as is evident from Figure 5a, ranging
between 0.1–1%. The MRD in BM (n = 93) (Figure 5b)
simultaneously was also high at the end of induction 1
(6th week of treatment), when according to MCP841 pro-
tocol BM aspirate was taken for the second time, the first
time being at diagnosis. These patients relapsed at some
point during maintenance therapy and accordingly may
be designated as high-risk patients. Out of six, two of
them died after relapse, while the remaining four attained
CR.
b. Assessment of OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19+ 
or OAcSGP+CD7+CD3+ lymphoblasts capable of detecting relapse 
few weeks prior to clinical relapse
The remaining 11 patients (10.09% of n = 109 patients)
susceptible for relapse had MRD within the normal range
initially which became higher just prior to clinical relapse
(Figure 6). MRD for these children increased to more than
0.1% in PB (Figure 6a) and 0.7% in BM (Figure 6b), irre-
spective of B or T-lineage ALL. In accordance with the pre-
vious group (Figure 5) having susceptibility of relapse
predicted by less clearance of lymphoblasts, this group
also had relapse mainly during the maintenance therapy.
Out of 11 patients (PB = 161 samples; BM = 81 samples),
relapse could however be detected only in 10 patients
(9.17%). Representative profiles of MRD of five patients
in PB (Figure 6a) and in BM (Figure 6b) have been
revealed. These children, prior to maintenance had a low
detectable level of MRD being 0.01–0.06% in PB and
0.04–0.08% in BM. However, on or after 20 weeks of
treatment each of these patients had a higher MRD in
both PB and BM followed by a clinical relapse at some
point during maintenance. This detection could be done
at least one month before the actual clinical relapse.
MRD in children susceptible to relapse, as predicted by the soaring MRD during induction 1 of the two-year treatment phase  under MCP841 protocol Figure 5
MRD in children susceptible to relapse, as predicted by the soaring MRD during induction 1 of the two-year 
treatment phase under MCP841 protocol. MRD of nine patients is shown from the first week of treatment till the end of 
two years unless otherwise expired. The data at diagnosis (0 week of treatment) has been given for comparison. Six patients 
relapsed of whom four attained CR (black circle) while two died post relapse (white rhombus). The remaining three patients 
inspite of initial high MRD remained in CR throughout (black triangle). a. Represents the MRD in PB. b. Represents the MRD in 
BM.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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Quantification of leukemic blasts by flow cytometry using admix assay Figure 7
Quantification of leukemic blasts by flow cytometry using admix assay. a. Dilutions of diagnostic samples admixed to 
PB or BM samples, from various time-points of follow-up during chemotherapy for lineage-unrelated leukaemia (e.g. B-lineage 
blasts into T-ALL follow-up BM and vice-versa) and analysed for MRD in R3 region using the same template as described in 
Materials and Methods. Correlation of the data was examined by regression analysis; line of identity is shown by (-). Diagnostic 
PB from B-ALL mixed with T-ALL follow-up (52 weeks of treatment, black rhombus); diagnostic BM from B-ALL mixed with T-
ALL follow-up (52 weeks of treatment, black triangle); diagnostic BM from T-ALL mixed with B-ALL follow-up (90 weeks of 
treatment, O); diagnostic BM from T-ALL mixed with B-ALL follow-up (104 weeks of treatment, black square) b. Dilutions of 
the REH (B-ALL, white triangle) and MOLT-4 (T-ALL, white rhombus) cell lines were made with normal PBMC and analysed as 
above.
MRD in children who relapsed after a few weeks of high MRD in PB and BM during the two-year treatment phase under  MCP841 protocol Figure 6
MRD in children who relapsed after a few weeks of high MRD in PB and BM during the two-year treatment 
phase under MCP841 protocol. MRD of five representative patients are shown (black circle) from first week of treatment. 
The data at diagnosis has been given for comparison. a. Represents the MRD in PB. b. Represents the MRD in BM.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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Detection of minimum number of OAcSGP+CD10+CD19+ 
or OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+ cells in a 
heterogeneous population to attest the sensitivity of MRD 
assay
Initially to simulate the in vivo scenario, MRD was
assessed using leukemic blasts from diagnostic samples
admixed to PB or BM samples, as the case may be, from
various time-points of follow-up during chemotherapy
for lineage-unrelated leukaemia (Figure 7a). One OAc-
SGP+CD10+CD19+,  OAcSGP+CD34+CD19+  or  OAc-
SGP+CD7+CD3+  cell could be detected in a total
population of 10,000 lymphocytes. The estimate of leuke-
mic cell content in each mixture was extremely accurate
(r2 = 0.96). Similarly, the assay was repeated using a het-
erogeneous cell population of PBMCN with ALL cell lines.
In this mixed population, similar detection of MRD was
possible for OAcSGP+CD10+CD19+  or  OAc-
SGP+CD7+CD3+ population (r2 = 0.99, Figure 7b).
Discussion
Immunophenotype, ploidy, chromosomal abnormalities,
gene rearrangements and clinical parameters are exten-
sively used for treatment stratification, but none of these
prognostic factors is totally accurate. Flow cytometry,
however, has the potential for accurate quantification of
MRD [30-37]. Although several strategies have been
adopted for treatment in childhood cancer [38], interest
in the use of biomarkers to evaluate the clinical status of
the patient and the future risk or relapse still remains a
challenge. Assessment of the O-acetylated sialoglycan pro-
file is a relatively unexplored domain in leukaemia sialo-
biology where the amplified expression of OAcSGP has
been established as a vital ALL-associated determinant
[3,15,19,20,25].
According to existing literature, the rate of post-chemo-
therapy (after two-years of therapy under MCP841 proto-
col) relapse rate is very high in India [2]. About 70% of all
relapses occur within four years from the start of therapy.
Due to the socio-economic scenario in India, a large
number of children, especially from weaker section of
society, expire because of the adverse effect of the lethal
doses of chemotherapy or due to the inability to bear the
expenses of treatment. Our aim was to design a MRD tem-
plate that would successfully unveil the disease status of
these patients, both in PB and BM during the treatment
regimen and correlate with the clinical symptom in a two-
year longitudinal follow-up study by flow cytometry. The
over expression of OAcSGP on lymphoblasts, irrespective
of their lineage, at onset of the disease, makes it a univer-
sal marker for paediatric ALL [15]. Therefore, we have
explored its differential expression along with other line-
age-specific antigens and have established the compe-
tence of the triple colour over single and double colour
template for monitoring MRD in these children.
The current investigation demonstrates the potential of
the designed templates OAcSGP+CD10+CD19+ or  OAc-
SGP+CD34+CD19+ or OAcSGP+CD7+CD3+ for successful
diagnosis and evaluation of the disease status during the
two-year chemotherapy, suggesting its application in
MRD detection and prediction of impending relapse in
ALL both in PB and BM. The level of MRD detection is
0.01% i.e., 1 cancerous cell in 104 lymphocytes can be
detected using the above mentioned templates Failure in
early clearance of these lymphoblasts during the initial
few weeks of treatment (till the end of induction 1)
showed high risk of relapse within the two-year treatment
phase. The relapse can be forecasted few weeks prior to
clinical relapse by periodic monitoring of these patients,
even in PB. The MRD detection in BM correlated well with
PB in both B- and T-ALL.
Augmented expression of OAcSGP at diagnosis and its
subsequent decrease during the treatment phase, irrespec-
tive of the lineage, triggered us to use it as an indicator for
MRD detection in childhood ALL. Using OAcSGP as the
only marker to monitor MRD could not improve the sen-
sitivity of detection below 5% as corroborated by our ear-
lier observation [15]. Moreover, 5–10% of MNCs from
normal donor also expressed OAcSGP on their surface,
though with minimum the antigen density (MFI = 10–50
au). Therefore, an ALL-specific template was required for
successful MRD detection. Two-colour flow-cytometric
study enabled the sensitivity to increase only up to 0.1%
[20]. This phenomenon has also been highlighted in
Table 2, where in spite of a 100% specificity, indicating
zero cross-reactivity, the single or dual marker method of
MRD detection could not be used. This paved the path for
the three-colour flow-cytometric study for further increas-
ing the sensitivity of MRD detection using Achatinin-H
along with two other lineage-specific markers for B/T-ALL
where detection level was 0.01%.
For the MRD detection, emphasis has been given on the
inclusion of only those CD markers whose expressions
were upregulated at the onset of the disease. Therefore, in
addition to OAcSGP, we have taken into consideration
two other lineage-specific markers, templates being OAc-
SGP+CD10+CD19+,  OAcSGP+CD34+CD19+  or  OAc-
SGP+CD7+CD3+, the former two for the MRD detection in
B-ALL and the latter for T-ALL. CD34 was included in the
template only for those patients who had a low percentage
(5–8%) of CD10+ cells at diagnosis. The detection level of
MRD thus improved to 0.01% (Figure 2, Table 1). This
observation was also demonstrated by the admixed exper-
iment (Figure 7a, b) in which we could unequivocally
detect the leukaemia-derived signals in dilutions contain-
ing at least two leukemic cells in 104 normal cells (r2 =
0.99), thereby suggesting the proficiency of the templates.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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The threshold of percent positive cells was used for MRD
detection. Cells positive for all the three antigens viz.,
OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19 or OAc-
SGP+CD7+CD3+ (as defined by the R3 gating) were con-
sidered to be the MRD present in the patient. The MRD in
normal donor and in patients with other haematological
diseases was absent (Figure 3) and therefore this was used
as negative control for all subsequent MRD analysis of
children with ALL. Patients at diagnosis were tested for the
presence of the same phenotype of cells for comparison as
positive control. Using these standards for evaluation, the
ALL patients in CR have an average MRD of 0.03 ± 0.01%
(PB) and 0.05 ± 0.015% (BM), irrespective of their line-
age, suggesting superior prognosis as substantiated by
clinical data (Table 1). Out of the total 109 patients stud-
ied during this two-year longitudinal follow-up study,
81.65% were in CR throughout the chemotherapeutic reg-
imen. As because MRD detection using these templates
could be done in no other haematological malignancy
except ALL, therefore, the aforesaid templates can be con-
sidered to be ALL-specific.
Clinical relapse was encountered in 16 patients during the
maintenance phase of treatment. Two groups of patients
highly susceptible to relapse could be identified from this
study population. The first cluster of such high-risk
patients had high MRD during induction 1, in both PB
and BM, with a consequent clinical relapse during 48–76th
week of treatment i.e., between second and fourth main-
tenance. Therefore, presence of MRD beyond the average
range during induction 1 has great prognostic significance
predicting relapse during maintenance therapy. 8.26%
patients of the total patient population showed this trend;
however, only 5.5% relapsed as predicted. Four of these
patients attained CR during 5th and 6th maintenance while
two of them died (Figure 5). The fact that three patients
were in CR in spite of their high MRD within the first five
weeks of treatment was probably due to their better
response to chemotherapy compared to their counterparts
coming across relapse. As the patients are monitored less
frequently during maintenance therapy, once in three
months, the majority of the relapses during this period
can be accounted for. The other group of patients at risk of
relapse exhibited high MRD few weeks prior to clinical
relapse (Figure 6). They had average MRD during the first
20 weeks of treatment, which increased after this period
terminating in a clinical relapse. In this group of patients,
the trend was seen in 10.09% out of which 9.17%
relapsed. 8 of these patients went into CR while two of
them died post relapse. Therefore, close monitoring of
children during the treatment will help in modifying the
intensification of the treatment. This observation has
been supported by earlier information on MRD, in which
monitoring patients during the first three months of treat-
ment is able to distinguish patients with good prognosis
from those with poor prognosis [30].
In general, as the normal counterparts of T-lineage ALL
cells are immature T cells, which are confined to the thy-
mus, detection of MRD simply consists of the identifica-
tion of immature T cells outside the thymus, i.e. in the BM
or in the PB. In contrast, the normal counterparts of B-ALL
reside in BM, referred to as 'haematogones'. They are
actively proliferating after chemotherapy or transplanta-
Table 2: Sensitivity and specificity of the templates used for the detection of MRD in children with ALL
*Cell surface antigen 1Sensitivity (%) 2Specificity (%) 3Detection level of MRD
OAcSGP 100 100 Till 5%
CD19 84.27 100
CD10 58.43 100
CD34 25.8 100
CD3 15.7 100
CD7 15.7 100
OAcSGP, CD19 84.27 100 Till 0.1%
OAcSGP, CD10 58.43 100
OAcSGP, CD34 25.8 100
OAcSGP, CD3 15.7 100
OAcSGP, CD7 15.7 100
CD19, CD10 58.43 100
CD19, CD34 25.8 100
CD3, CD7 15.7 100
OAcSGP, CD10, CD19 58.43 100 Till 0.01%
OAcSGP, CD34, CD19 25.8 100
OAcSGP, CD7, CD3 15.7 100
* Single or a combination (double or triple colour) of cell surface antigen/s used for the MRD assay
1 Probability of a positive test among patients with disease
2 Probability of a negative test among patients without disease
3 Detection level of the presence of diseased cells in the patientBMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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tion in BM, and can also be found in low proportions in
PB [32]. Therefore the strategy for MRD detection in B-
ALL is less straightforward than T-ALL. The use of PB for
the detection of MRD is debatable because subtle leukae-
mia-associated deregulation of gene expression extends to
many other molecules normally expressed during B-cell
differentiation [33,34]. However two studies [35,36] have
shown that paired MRD values in BM and PB are highly
concordant in T-ALL. Conversely, large differences fre-
quently occur in B-ALL, where levels are higher in BM than
that of PB. Interestingly, we could detect MRD in both PB
and BM not only in CR but also for predicting impending
relapses. In the category of patients, failing to clear lym-
phoblasts during the first induction of chemotherapy,
MRD in PB was very high between 1–6 weeks, corrobo-
rated by higher MRD in BM on 6th  week (Figure 5).
Accordingly at the time of relapse, very high MRD could
be detected in PB as well as BM. Similarly in the second
high-risk group of patients, elevation in MRD few weeks
prior to relapse occurred irrespective of PB and BM (Figure
6). In all the aforesaid comparisons although the MRD in
PB is significantly less than that in BM (p value < 0.0001),
the interesting piece of information that can be retrieved
is that MRD in BM is being reflected in PB. As comparable
Details of the study population in childhren with ALL, beginning with diagnosis and ending with the completion of MCP841 pro- tocol Figure 8
Details of the study population in childhren with ALL, beginning with diagnosis and ending with the completion 
of MCP841 protocol. n = Number of patients; percentage of patients among the total population is indicated in parentheses.BMC Cancer 2008, 8:40 http://www.biomedcentral.com/1471-2407/8/40
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MRD can be detected even in PB, the strenuous process of
BM aspiration may be evaded.
In this investigation, each patient has been monitored 29
times (PB-18 times and BM-11 times) throughout the
two-year tenure of treatment under MCP841. As the sam-
ples were obtained as per the MCP841 protocol, for clini-
cal investigation, we have utilized the opportunity to use
them for the MRD assay for standardization of our tem-
plate. Although monitoring a patient so frequently is dif-
ficult and expensive for a third world country like India,
such an elaborate monitoring may not be needed. Minute
quantity of lectin (0.04 μg/μl per test) used for the assay,
being 1.2 μg for a patient in two years offers a cheaper
source of diagnostic approach.
Conclusion
The templates used in this investigation enable MRD
detection in both PB and BM of every B-and T-ALL patient.
Patients in CR have MRD between 0.02–0.04% in PB and
0.04–0.06% in BM irrespective of B/T-ALL. Although the
difference between the MRD in PB and BM is significant
(p value < 0.0001, Table 1), the clinical status of the
patients can be revealed even from PB. In the study popu-
lation comprising 130 children with ALL at diagnosis, 21
patients could not be monitored after diagnosis, as they
were not available. Among the remaining 109 children,
81.65% attained and remained in CR throughout the two-
year chemotherapeutic regimen while 18.34% showed
abnormal pattern in MRD. 8.26% of these patients had
high MRD during induction 1 with subsequent relapse in
5.5% patients during maintenance. Among the relapsed
patients, 1.83% died while the remaining attained
CR.10.09% of the patients showed elevated MRD few
weeks before relapse. While one of them escaped relapse,
7.34% experienced so, accomplishing CR and 1.83%
dying post relapse (Figure 8).
It is interesting to note that 89 patients in spite of being in
CR during the two-year chemotherapy, showed an observ-
able MRD and therefore may not be declared as normal.
Therefore, we recommend MRD study beyond two-year
follow-up to monitor the lowering of MRD in these chil-
dren, thereby ensuring their disease free survival.
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